Modulatory effects of CeO2 nanoparticles on bleomycin-induced active pulmonary disease processes in animal and human airway epithelium models

TL;DR

This study explores how cerium oxide nanoparticles affect lung injury in animal and human models, showing both protective and harmful effects depending on timing.

Contribution

The study demonstrates that CeO2NPs can modulate lung injury responses during active disease processes, emphasizing the importance of exposure timing.

Findings

CeO2NP exposure reduced fibrotic staining and inflammatory gene expression in bleomycin-treated rats.

In vitro models showed CeO2NPs modulated some bleomycin-induced responses but lacked whole-body complexity.

Findings highlight the context-dependent effects of CeO2NPs in pre-existing lung injury.

Abstract

Understanding the impacts of inhaled insoluble nanomaterials as they are encountered in the environment and workplace, in injured lungs remains limited, particularly with respect to their role in the progression or mitigation of lung pathology. While some studies suggest potential protective effects of cerium(IV) oxide nanoparticles (CeO2NPs) under certain conditions, their influence during active disease processes is unclear. This study builds on prior work to investigate the effects of CeO2NP aerosols on bleomycin-induced pulmonary injury and active disease processes.

To establish conditions of active pulmonary disease processes, bleomycin was used in both animal and airway epithelium models. Male Sprague-Dawley rats were intratracheally instilled with bleomycin or saline (control) followed by nose-only inhalation exposure to CeO2NP aerosols (diameter of ~ 43 nm) or control for 3 h per day for 4 days per week for one or two weeks. At three days postexposure, the animals were sacrificed for analysis of bronchoalveolar lavage (BAL) fluid, lung histopathology and global mRNA expression. Comparative in vitro studies were conducted to investigate biological responses at the cellular level, using 3D human small airway epithelium cultures (SmallAir™) exposed to CeO2NP aerosols (with a diameter of ~ 86 nm) at the air-liquid-interface at deposition doses comparable to those received in vivo in the small airway.

In vivo, bleomycin treatment resulted in an increase in total BAL cells and fibrotic staining, and significant induction of inflammatory and oxidative stress, as shown by mRNA sequencing analysis. One week of exposure to CeO2NPs modified these responses by attenuating fibrotic staining and reducing the expression of genes associated with lung function, inflammation and epithelial-mesenchymal transition (EMT). In vitro, CeO2NP exposure modulated some bleomycin-induced cellular responses, although these models do not fully capture the complexity of whole body and tissue systems, highlighting limitations and considerations for future in vitro exposure studies.

In this study, inhaled CeO2NPs modulated lung injury responses in the context of active disease, with both potential protective effects and adverse outcomes. These findings demonstrate that the timing of CeO2NP exposure relative to disease progression is critical and highlight the need for hazard assessment frameworks to consider context-dependent effects, particularly in the presence of pre-existing lung injury.

The online version contains supplementary material available at 10.1186/s12989-026-00658-9.

Figures